Massey Quick Simon & CO. LLC Sells 334 Shares of Edwards Lifesciences Corp (NYSE:EW)

Massey Quick Simon & CO. LLC trimmed its position in Edwards Lifesciences Corp (NYSE:EW) by 70.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 141 shares of the medical research company’s stock after selling 334 shares during the period. Massey Quick Simon & CO. LLC’s holdings in Edwards Lifesciences were worth $26,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. FTB Advisors Inc. acquired a new stake in Edwards Lifesciences during the 1st quarter worth approximately $25,000. TRUE Private Wealth Advisors acquired a new position in Edwards Lifesciences in the second quarter valued at about $26,000. Evolution Wealth Advisors LLC acquired a new position in Edwards Lifesciences in the second quarter valued at about $29,000. M&R Capital Management Inc. acquired a new position in Edwards Lifesciences in the second quarter valued at about $29,000. Finally, Next Capital Management LLC raised its stake in Edwards Lifesciences by 297.7% in the second quarter. Next Capital Management LLC now owns 171 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 128 shares in the last quarter. Institutional investors and hedge funds own 81.90% of the company’s stock.

Shares of Edwards Lifesciences stock traded down $0.10 on Wednesday, reaching $221.91. 244,576 shares of the company’s stock were exchanged, compared to its average volume of 1,154,940. The company has a market capitalization of $46.40 billion, a P/E ratio of 47.21, a price-to-earnings-growth ratio of 2.76 and a beta of 0.87. Edwards Lifesciences Corp has a 52 week low of $136.44 and a 52 week high of $226.41. The firm’s 50-day moving average is $204.84 and its two-hundred day moving average is $185.93. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.48 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.05. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The company’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.24 EPS. On average, analysts expect that Edwards Lifesciences Corp will post 5.34 EPS for the current fiscal year.

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 372 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $214.53, for a total transaction of $79,805.16. Following the transaction, the vice president now directly owns 18,010 shares in the company, valued at approximately $3,863,685.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Schack Wesley W. Von sold 3,000 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $217.27, for a total value of $651,810.00. Following the transaction, the director now owns 1,737 shares in the company, valued at $377,397.99. The disclosure for this sale can be found here. Insiders have sold a total of 137,951 shares of company stock worth $27,076,240 over the last 90 days. Company insiders own 1.63% of the company’s stock.

Several brokerages have commented on EW. BMO Capital Markets boosted their target price on Edwards Lifesciences from $204.00 to $224.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Wells Fargo & Co boosted their target price on Edwards Lifesciences from $207.00 to $220.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. BTIG Research reissued a “hold” rating on shares of Edwards Lifesciences in a research note on Thursday, July 25th. Citigroup set a $159.00 price objective on Edwards Lifesciences and gave the company a “sell” rating in a research note on Friday, July 26th. Finally, Bank of America reaffirmed a “buy” rating and issued a $225.00 price objective (up previously from $215.00) on shares of Edwards Lifesciences in a research note on Wednesday, July 24th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $204.74.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: Special Dividends

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.